Corvus Pharmaceu Stock Price, News & Analysis

Corvus Pharmaceuticals (NASDAQ: CRVS) has announced the initiation of a Phase 2 clinical trial of soquelitinib for treating Autoimmune Lymphoproliferative Syndrome (ALPS), a rare genetic disease. The trial will be conducted by NIH/NIAID in partnership with Corvus.

The study will enroll up to 30 patients aged 16 or older with confirmed ALPS-FAS, testing two dosing cohorts of 200mg and 400mg twice daily for up to 360 days. The primary endpoint focuses on reducing splenomegaly and lymph node volumes, with secondary endpoints including safety and tolerability.

This marks the third indication for soquelitinib, alongside its ongoing Phase 3 trial for peripheral T cell lymphoma (PTCL) and Phase 1 trial for atopic dermatitis. Corvus plans to initiate an additional Phase 1 trial for solid tumors in Q2 2025.

Corvus Pharmaceuticals (NASDAQ: CRVS) has announced its participation in the Oppenheimer 35th Annual Healthcare Life Sciences Conference, a virtual event. The clinical-stage biopharmaceutical company's leadership team will deliver a corporate overview presentation on Tuesday, February 11, 2025, at 9:20 am ET.

The company will also conduct one-on-one meetings with investors during the conference. A webcast of the presentation will be accessible through the investor relations section of Corvus's website, with availability both live and for 90 days following the event.

Corvus Pharmaceuticals (NASDAQ: CRVS) has released new interim data from its Phase 1 clinical trial of soquelitinib for atopic dermatitis. The trial, which includes data from 26 patients across two cohorts, showed promising results with 26% of treated patients achieving IGA 0 or 1 and 37% achieving EASI 75, while no placebo patients reached these endpoints.

The study evaluated two dosing regimens: Cohort 1 with 100 mg twice daily (12 patients) and Cohort 2 with 200 mg once daily (7 patients), against placebo groups. All Cohort 2 patients completed the 28-day treatment period with no significant safety issues or laboratory abnormalities. The trial is designed to enroll 64 patients total across four cohorts, with full results expected in Q2 2025.

Corvus Pharmaceuticals (NASDAQ: CRVS) has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, scheduled for January 13-16, 2025. Richard A. Miller, M.D., the company's president and chief executive officer, will engage in one-on-one investor meetings and deliver a corporate overview presentation.

The presentation is scheduled for Wednesday, January 15, 2025, at 2:15 pm ET / 11:15 am PT. An audio webcast will be available live and accessible for 30 days after the event through the investor relations section of Corvus's website.

Corvus Pharmaceuticals (NASDAQ: CRVS) reported positive interim data from its Phase 1 clinical trial of soquelitinib for atopic dermatitis. The trial's lowest dose cohort demonstrated favorable safety and efficacy profiles. Key findings include:

- Mean EASI score reduction of 55.9% at 28 days and 69.1% at 58 days in the treatment group, compared to 27.0% and 19.1% in placebo

- Nine of 12 patients achieved EASI 50 at day 28, with three achieving EASI 75 and one reaching EASI 90

- No significant safety issues were observed during the trial

Additionally, Samlyn Capital exercised warrants to purchase 3,633,978 shares, providing approximately $12.7 million in cash proceeds to Corvus.

Corvus Pharmaceuticals (NASDAQ: CRVS) announced it will release interim data from its Phase 1 clinical trial of soquelitinib for atopic dermatitis on December 18, 2024. The trial is a randomized, double-blind, placebo-controlled study evaluating the drug in patients with moderate to severe atopic dermatitis. The company will host a conference call and webcast at 8:00 a.m. ET / 5:00 a.m. PT to present the data, which will also be released via press release. The presentation will include slides and be accessible through a toll-free domestic line or international dial-in, with a webcast replay available on the company's website for 60 days.

Corvus Pharmaceuticals (NASDAQ: CRVS) announced the publication of preclinical data for soquelitinib, their lead ITK inhibitor program, in npj Drug Discovery. The research demonstrates soquelitinib's potential as a novel approach to modulate tumor immunity through its mechanism of action - suppressing Th2 and Th17 cytokine production while sparing Th1 cytokines.

The data shows that soquelitinib increases effector function of cytotoxic CD8 positive T cells and enhances memory T cell function. The company is currently conducting a Phase 3 clinical trial for relapsed peripheral T cell lymphoma (PTCL) and a Phase 1 trial for atopic dermatitis, with plans to initiate another Phase 1 trial in solid tumors.

Corvus Pharmaceuticals announced new preclinical data showing that soquelitinib, their lead ITK inhibitor, could potentially prevent lung damage, inflammation, and pulmonary hypertension caused by systemic sclerosis. The study used Fra-2 transgenic mice, which mirror human systemic sclerosis features. After seven weeks of oral soquelitinib treatment, mice showed significant reduction in lung infiltration and fibrosis, improved clinical scores, reduced vascular smooth muscle hypertrophy, and lower right ventricular systolic blood pressure. These results were validated in a second bleomycin lung injury model.

Corvus Pharmaceuticals provided Q3 2024 updates on its clinical programs. The company is advancing two clinical trials for soquelitinib: a Phase 3 trial in Peripheral T Cell Lymphoma (PTCL) and a Phase 1 trial in atopic dermatitis, with interim data expected in December 2024. Financial highlights include cash position of $41.7M as of September 30, 2024, with an additional $5.9M from warrant exercises in October. Q3 net loss was $40.2M, including a $32.8M non-cash warrant liability loss. R&D expenses increased to $5.2M from $4.0M year-over-year. The company expects current cash to fund operations into 2026.